Verona Pharma Share Discussion Threads

[haroldthegreat] 25/1/2018 00:32

who was that presentation made to ?

[bewise2] 24/1/2018 19:13

Big news year with vrp, fingers crossed!

[bewise2] 24/1/2018 19:09

Still some life, lol.......Jan 18 Presentation

[haroldthegreat] 24/1/2018 14:57

Everyone died who posted here ? Calling Mary Celeste crew !

[127tolmers] 30/11/2017 16:11

Decided to follow the Chairman's purchase @ 107p. Has he called the bottom? Not clear if the price setters are now US and GBP strength is exerting downward pressure on share price

[insideryou] 22/11/2017 14:07

U see. Candy from a baby. No buyers or support until the shorts turn sides. Soon soon sheep

[haff1] 17/11/2017 13:23

Thanks for the thoughts timbo..

[meijiman] 17/11/2017 11:01

There must be better prospects than this. I keep looking at Vernalis -every man and his dog are negative.. often a good time to buy.

[timbo003] 17/11/2017 10:36

>>>>haff1

I think providing they concentrate on the original objective, i.e. to get it approved as a nebulised solution for ER use (and post ER use) and they can generate data so they can make a pharmaco-economic argument that using nebulised RPL554 as rescue medication in ER (and afterwards to reduce readmissions), it should come good in the end.

The CF will be nice to have and so will a DPI and MDI formats, but they should concentrate on their knitting IMO.

[meijiman] 17/11/2017 10:28

would be interesting to hear views of the more expert posters on the prospects for this ? It's looking more and more like a dog. Woof woof.

[haff1] 17/11/2017 10:06

timbo. that would suggest we are all stuffed here then?

[insideryou] 16/11/2017 14:05

Heavily manipulated and shorted by those in dark glasses. Easy money. Why rob a Bank when you can steal money this easily

[timbo003] 16/11/2017 11:38

GSK received approval today in Europe for their triple combo (Trelegy Ellipta) for COPD:

[steven1404] 16/11/2017 11:24

Meu are recruiting for patients to trial rpl554 2 month study

[shakin not stirred] 15/11/2017 18:00

Bewise all good?? Really not to sure looking at the share price Shocked and maybe going to see some poor results from current trial.

[haff1] 09/11/2017 12:04

Its a shame the share price doesnt reflect this..

[bewise2] 07/11/2017 10:36

All good :)

[bonzo] 07/11/2017 09:20

Excellent News here. Recruiting ahead of plan is an encouraging sign, it means the clinicians are confident of success.

[rathean] 01/11/2017 08:06

Seriously who buys 8 shares? Hmm dip toes in now ahead of results or wait and see...

[bonzo] 27/9/2017 08:28

Certainly looks encouraging!

[timbo003] 27/9/2017 07:36

It may not be earth shattering news this morning, but it is another box to tick.

Circa 10% was delivered by the oral route via the nebuliser, that seems like a mighty efficient nebuliser, I thought he norm for drugs administered via the inhalation route was >20%.

I see that they have confirmed a long half life too, so that suggests that if any of the effects are systemic (anti-inflammatory effects?) they will probably have a sustained duration which would be consistent with once or twice a day dosing.

[haff1] 08/9/2017 09:27

Yes this is still grosly under priced but still needs that license with a major pharma to rocket. The market for the product is massive...

[127tolmers] 08/9/2017 08:43

Now regained my original target of 150 where I had previously sold half my EIS holding. It will be interesting to see if it breaks through the 200 & 300 resistance levels and if it ever regains the 600 level at which I would be a seller.

[lord buffett] 07/9/2017 23:57

At a closing price of $16.60 on Nasdaq and an exchange rate of $1.31, the Nasdaq price is equivalent to approximately £1.58 per share in the UK (based on 8 ordinary shares per ADS).

[bewise2] 07/9/2017 20:02

Up over 40% on Nasdaq